Hostname: page-component-77c89778f8-n9wrp Total loading time: 0 Render date: 2024-07-18T17:26:38.607Z Has data issue: false hasContentIssue false

Sphingomonas paucimobilis infection among a patient with a history of injection drug use: An opportunity for improvement of medical chart documentation

Published online by Cambridge University Press:  15 September 2020

Michael A. Goulart*
Affiliation:
Infection Prevention and Control, University of Florida Health Jacksonville, Jacksonville, Florida
Marko Predic
Affiliation:
Infection Prevention and Control, University of Florida Health Jacksonville, Jacksonville, Florida
Chad D. Neilsen
Affiliation:
Infection Prevention and Control, University of Florida Health Jacksonville, Jacksonville, Florida
*
Author for correspondence: Michael Goulart, E-mail: michael.goulart@jax.ufl.edu
Rights & Permissions [Opens in a new window]

Abstract

Type
Letter to the Editor
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved

To the Editor—At our level 1 academic trauma center in northeastern Florida, a patient developed a central-line–associated bloodstream infection (CLABSI) with Sphingomonas paucimobilis, an aerobic gram-negative bacillus that more commonly occurs in immunocompromised persons and is less commonly associated with nosocomial transmission. Reference Dworkin, Falkow, Rosenberg, Schleifer and Stackebrandt1Reference Toh, Tay, Kuar, Weng, Tang and Tan3 This patient was a female in her late twenties who was admitted for multifocal pneumonia after several days of cough and shortness of breath. Her medical history was remarkable for Hodgkin’s lymphoma, chronic hepatitis C infection, thrombocytopenia, neutropenia, excoriation, tobacco use, and injection drug use (oxycodone). She denied current drug use. A double-lumen power peripherally inserted central catheter (PICC) was placed and dressed with a transparent dressing and chlorhexidine-gluconate impregnated antimicrobial disc (BioPatch) according to hospital policy. Approximately 1 month into her stay, blood cultures were positive for S. paucimobilis. Medical staff had documented patient noncompliance with hospital polices, such as dressing changes, on multiple occasions. After a 57-day stay, the patient was discharged to home hospice.

Whether the patient acquired S. paucimobilis due to her immunocompromised state and/or noncompliance with hospital policies is unknown. There was a paucity of information regarding her past history of injection drug use, as documented by clinical staff during her admission. Current injection drug use may have contributed to the development of the CLABSI. Walayat et al Reference Walayat, Malik, Hussain and Lynch4 noted the isolation of S. paucimobilis in an injection drug user, which presented itself as acute phlebitis; these authors suspected the patient acquired the organism from using toilet water to mix heroin prior to injecting. Reference Walayat, Malik, Hussain and Lynch4 We urge clinicians to thoroughly document past drug use, especially among past and current injection drug users, to note when suspected drug use has occurred, and/or to note suspicion if a patient has accessed their own vascular catheter. This is critical in wake of the ongoing opioid epidemic linked to injection drug use, which has affected many states across the United States, including Florida, which has also been facing an ongoing outbreak of the hepatitis A virus. Since January 2018, more than one-third of reported cases in the state have reported injection drug use. 5 According to the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network definitions, even if a patient accesses their own vascular catheter during their hospital stay, whether through injection drug use or other means, and it meets the CLABSI case definition, it is still attributed to the reporting facility. 6 The CDC recommend that risk mitigation include a sitter for the patient and/or removing the tunneled catheter as soon as clinically possible. Providing a sitter may not always be feasible, especially in light of ongoing novel coronavirus pandemic. 6

Acknowledgments

None.

Financial support

No financial support was provided relevant to this article.

Conflicts of interest

All authors report no conflicts of interest relevant to this article.

References

Dworkin, M, Falkow, S, Rosenberg, E, Schleifer, K, Stackebrandt, E. The Prokaryotes. Vol 7. New York, NY: Springer-Verlag; 2007:206226.Google Scholar
Kilic, A, Senses, Z, Kurekci, A, Aydogan, H, Basustaoglu, A. P592 Nosocomial outbreak of Sphingomonas paucimobilis bacteraemia in an oncology and haematology unit. Int J Antimicrob Agents 2007;29:S137.10.1016/S0924-8579(07)70435-1CrossRefGoogle Scholar
Toh, HS, Tay, HT, Kuar, WK, Weng, TC, Tang, HJ, Tan, CK. Risk factors associated with Sphingomonas paucimobilis infection. J Microbiol Immunol Infect 2011;44:289295.10.1016/j.jmii.2010.08.007CrossRefGoogle ScholarPubMed
Walayat, S, Malik, A, Hussain, N, Lynch, T. Sphingomonas paucimobilis presenting as acute phlebitis: a case report. IDCases 2017;11:68.10.1016/j.idcr.2017.11.006CrossRefGoogle ScholarPubMed
Hepatitis A surveillance, July 2020. Florida Department of Health website. http://www.floridahealth.gov/diseases-and-conditions/vaccine-preventable-disease/hepatitis-a/surveillance-data/_documents/2020-july-hep-a-report.pdf. Published August 11, 2020. Accessed August 17, 2020.Google Scholar
NHSN frequently asked questions: central line-associated bloodstream infection. Centers for Disease Control and Prevention website. https://www.cdc.gov/nhsn/PDFs/faqs/FAQs-V-6_CLABSI.pdf. Accessed January 14, 2020.Google Scholar